Colliers’ 2025 Global Investor Outlook reveals renewed investor optimism in commercial real estate as pricing stabilizes 20-11-2024, 08:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai 18-09-2024, 22:07

Aegon hosts educational webinar on IFRS 17 and IFRS 9 9-03-2023, 16:35